# China NMPA Inspection - Guangzhou Tianyuan Biotechnology Co., Ltd - February 03, 2023

Source: https://www.globalkeysolutions.net/records/china_inspection/guangzhou-tianyuan-biotechnology-co-ltd/65ec0047-5b10-4bb2-ba9e-cb071b8e15e8/
Source feed: China

> China NMPA unannounced inspection for Guangzhou Tianyuan Biotechnology Co., Ltd published February 03, 2023. The National Medical Products Administration (NMPA) issued an announcement on February 3, 2023, detailing the outcomes of recent unannounced inspectio

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement No. 7 of 2023 from the National Medical Products Administration regarding the results of unannounced inspections of companies including Guangzhou Mingquan Biotechnology Co., Ltd.
- Company Name: Guangzhou Tianyuan Biotechnology Co., Ltd
- Publication Date: 2023-02-03
- Product Type: cosmetics
- Summary: The National Medical Products Administration (NMPA) issued an announcement on February 3, 2023, detailing the outcomes of recent unannounced inspections conducted on two companies: Guangzhou Mingquan Biotechnology Co., Ltd. and Guangdong Sirui Cosmetics Co., Ltd. The inspections, carried out under the authority of the NMPA, identified that both entities had committed violations of significant regulatory provisions. Specifically, the companies were found to be non-compliant with the "Cosmetics Supervision and Management Regulations" and the "Cosmetics Production Quality Management Standards," which are foundational for ensuring product quality and consumer safety in the cosmetic industry. Although the official announcement did not specify the exact nature of the violations, it confirmed that both companies acknowledged their respective shortcomings. To address these serious breaches and protect public health, the NMPA has taken decisive action. The Guangdong Provincial Drug Administration has been instructed to order both Guangzhou Mingquan Biotechnology Co., Ltd. and Guangdong Sirui Cosmetics Co., Ltd. to immediately cease their production and operational activities. This suspension is a prerequisite for them to undertake comprehensive rectification efforts to correct the identified deficiencies. Concurrently, the NMPA has launched a full investigation into the matter to ascertain the extent and implications of these regulatory failures.

Company: https://www.globalkeysolutions.net/companies/guangzhou-tianyuan-biotechnology-co-ltd/de378fd8-e2c8-406d-9032-2967f9e92380/